Novel Peptide Therapeutic Approaches for Cancer Treatment

Cells. 2021 Oct 27;10(11):2908. doi: 10.3390/cells10112908.


Peptides are increasingly being developed for use as therapeutics to treat many ailments, including cancer. Therapeutic peptides have the advantages of target specificity and low toxicity. The anticancer effects of a peptide can be the direct result of the peptide binding its intended target, or the peptide may be conjugated to a chemotherapy drug or radionuclide and used to target the agent to cancer cells. Peptides can be targeted to proteins on the cell surface, where the peptide-protein interaction can initiate internalization of the complex, or the peptide can be designed to directly cross the cell membrane. Peptides can induce cell death by numerous mechanisms including membrane disruption and subsequent necrosis, apoptosis, tumor angiogenesis inhibition, immune regulation, disruption of cell signaling pathways, cell cycle regulation, DNA repair pathways, or cell death pathways. Although using peptides as therapeutics has many advantages, peptides have the disadvantage of being easily degraded by proteases once administered and, depending on the mode of administration, often have difficulty being adsorbed into the blood stream. In this review, we discuss strategies recently developed to overcome these obstacles of peptide delivery and bioavailability. In addition, we present many examples of peptides developed to fight cancer.

Keywords: PCNA; covalent-based peptide inhibitors; drug delivery; peptide therapeutic.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Cell-Penetrating Peptides / pharmacology
  • Humans
  • Models, Biological
  • Nanoparticles / chemistry
  • Neoplasms / drug therapy*
  • Peptides / pharmacology
  • Peptides / therapeutic use*
  • Proliferating Cell Nuclear Antigen / metabolism


  • Cell-Penetrating Peptides
  • Peptides
  • Proliferating Cell Nuclear Antigen